Key result
Oral N-acetylcysteine treatment for 6 weeks significantly improved endothelium-dependent vasodilatation (FMD%) from 7.5% to 10.59% (p<0.01) in patients on hemodialysis.
Why the study?
Does oral N-acetylcysteine improve endothelial dysfunction in hemodialysis patients?
Population
30 uremic patients on hemodialysis and 13 healthy controls
Comparison
Oral N-acetylcysteine 600 mg twice daily for 6… vs Baseline measurements and healthy controls
Design
Cohort
Follow-up
6 weeks
Authors
Loading...
May support endothelial benefit of oral NAC in hemodialysis; hypothesis-generating and requires randomized confirmation.
Observational (n=43)
Does oral N-acetylcysteine improve endothelial dysfunction in hemodialysis patients?
Absolute Event Rate: 10.59% vs 7.5%
p-value: p=<0.01
Oral N-acetylcysteine (1200 mg/day) for 6 weeks significantly improves endothelium-dependent vasodilatation in hemodialysis patients.
Şahin et al. (2007) conducted an observational in K/DOQI stage 5 chronic kidney disease on hemodialysis (n=43). N-acetylcysteine (NAC) vs. Baseline (before treatment) was evaluated on Endothelium-dependent vasodilatation (flow-mediated dilatation; FMD%) (p=<0.01). Oral N-acetylcysteine treatment for 6 weeks significantly improved endothelium-dependent vasodilatation (FMD%) from 7.5% to 10.59% (p<0.01) in patients on hemodialysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: